Table 54Changes in lipid parameters (mean change from baseline, mg/dL)

Hanefeld, 200746Scott, 200836Charbonnel, 200647Mohan, 200945a
S100PBOS100/METRosi/METPBOS100PBOS100PBO
Total cholesterol+6.1−3.0+8.1+26.2+17.4+1.93+5.4NRNR
HDL+2.4+0.2+0.6+3.5+1.8+1.16+0.77+0.3+0.1
LDL+4.9−3.7+9.8+20.4+12.8+1.93+1.93+5.3+4.3
TG−5.6+1.7−14.5−1.8+20.1−7.08+19.46−10+10.6

Abbreviations: HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; PBO, placebo; pio, pioglitazone; Rosi/MET, rosiglitazone added to metformin; S100/MET, sitagliptin added to metformin; S/Pio, sitagliptin added to pioglitazone; TG, triglyceride.

a

Data received from manufacturer

From: Results

Cover of Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations
Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report [Internet].
Jonas D, Van Scoyoc E, Gerrald K, et al.
Portland (OR): Oregon Health & Science University; 2011 Feb.
Copyright © 2011, Oregon Health & Science University.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.